{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"The number of patients who experienced complete Response (CR) within the first four cycles. By modern response criteria, those with partial response (PR) or stable disease with all target lesions with Deauville scores \\<=3 after cycle 4 are also considered as CR. Patients were assessed after treatment with four cycles of gemcitabine with brentuximab vedotin. CR was only reported for Dose level 2 across both phases of study.","groups":[{"description":"Patients receive brentuximab vedotin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 100 minutes on days 1 and 8. Treatment repeats every 21 days for up to 15 more courses in the absence of disease progression or unacceptable toxicity. Patients with CR after any course may go off protocol therapy for stem cell transplant.\n\nBrentuximab Vedotin: Given IV\n\nGemcitabine Hydrochloride: Given IV","id":"OG000","title":"Treatment (Brentuximab Vedotin, Gemcitabine Hydrochloride)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients (N=42) at Dose Level 2 (brentuximab vedotin 1.8 mg/kg with gemcitabine). 4 patients were excluded. 3 patients did not receive dose level 2 and 1 patient was ineligible due to exceeding the prescribed interval between disease evaluation and study entry.","reportingStatus":"POSTED","timeFrame":"After 4 cycles (21 days per cycle) of protocol therapy","title":"The Number of Patients With Relapsed or Refractory HL Who Achieved Complete Response (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}